Novo Nordisk (NVO) convinced the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board to dismiss challenges to two of its patents for the active compound in its weight-loss drugs Ozempic and Wegovy, Bloomberg’s James Arkin reports. The tribunal determined that Mylan, now part of Viatris (VTRS), did not meet the requirements for an inter partes review of the two patents, the author notes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Mylan challenge of two GLP-1 patents denied, Bloomberg says
- Novo Nordisk late-day strength attributed to Wegovy patent ruling
- Novo Nordisk announces FDA approval of Rivfloza injection for PH1
- Argus starts Novo Nordisk at Buy, sees valuation justified by growth outlook
- Novo Nordisk initiated with a Buy at Argus